

**ABRIDGED VERSION OF PROSPECTUS**

Of

**INDO-BANGLA PHARMACEUTICALS LIMITED**

**(1) Name(s) and address(es), telephone numbers, web addresses, e-mails, fax numbers and contact persons of the issuer, issue manager and underwriter;**

**Issuer:**

| <b>Name &amp; Address</b>  | <b>Telephone &amp; Fax Number, E-mail, Web Address</b>  | <b>Contact Person</b>                                 |
|--|---|---|
| <b>Indo-Bangla Pharmaceuticals Limited (IBPL)</b><br>729, College Road, Barisal Sadar, Barisal-8200. | Tel: +88-04-3161028<br>Fax: +88-04-312174977<br>Email: info@indo-banglapharma.com<br>Web: www.indo-banglapharma.com | <b>Md. Faruque Hossain</b><br>Chief Financial Officer |

**Issue Manager:**

|   |   |   |
|---|---|---|
| <b>AFC Capital Limited</b><br>Saiham Sky View Tower (11 <sup>th</sup> Floor), 45 Bijoy Nagar, Dhaka-1000.                   | Tel: +88-02-8392371<br>Fax: +88-02-8392372<br>Email: capital.afcl@gmail.com<br>Web: www.afcl.asia                 | <b>Mahbub H. Mazumdar FCMA</b><br>Chief Executive                     |
| <b>EBL Investments Limited</b><br>59 Motijheel C/A, 1 <sup>st</sup> Floor, Dhaka-1000.                                      | Tel: +88-02-7118975<br>Fax: +88-02-7120251<br>E-mail: info@eblinvestments.com<br>Web: www.eblinvestments.com      | <b>Pankaj Kumar Mutsuddi</b><br>Managing Director<br>(Current Charge) |
| <b>CAPM Advisory Limited</b><br>Tower Hamlet (9 <sup>th</sup> Floor)<br>16, Kemal Ataturk Avenue<br>Banani C/A, Dhaka-1213. | Tel: +88-02-9822391-2<br>Fax: +88-02-9822393<br>E-mail: contact@capmadvisorybd.com<br>Web: www.capmadvisorybd.com | <b>Tania Sharmin</b><br>Managing Director & CEO                       |

**Underwriter:**

|  |  |   |
|--|--|---|
| <b>AFC Capital Limited</b><br>Saiham Sky View Tower (11 <sup>th</sup> Floor), 45 Bijoy Nagar, Dhaka-1000.                  | Tel: +88-02-8392371<br>Fax: +88-02-8392372<br>Email: abparvez_afcl@yahoo.com<br>Web: www.afcl.asia             | <b>Md. Abul Bashar Parvez</b><br>Deputy Manager                       |
| <b>EBL Investments Limited</b><br>59 Motijheel C/A, 1 <sup>st</sup> Floor, Dhaka-1000.                                     | Tel: +88-02-7118975<br>Fax: +88-02-7120251<br>E-mail: pankaj@eblinvestments.com<br>Web: www.eblinvestments.com | <b>Pankaj Kumar Mutsuddi</b><br>Managing Director<br>(Current Charge) |
| <b>NBL Capital and Equity Management Limited</b><br>Printers Building (8 <sup>th</sup> Floor), 5 Rajuk Avenue, Dhaka-1000. | Tel: +88-02-7118974<br>Fax: +88-02-7118840<br>E-mail: knaher@gmail.com<br>Web: www.nblcml.com                  | <b>Kamrun Naher</b><br>Chief Executive Officer                        |
| <b>Janata Capital and Investment Limited</b><br>48, Motijheel (3 <sup>rd</sup> Floor), Dhaka-1000                          | Tel: +88-02-7114375<br>Fax: +88-02-7110496<br>E-mail: info@jil.com.bd<br>Web: www.jil-bd.com                   | <b>Dina Ahsan</b><br>Chief Executive Officer                          |

**(2) Amount, type and offering price of the securities on a per unit and aggregate basis of securities being issued;**

Public issue of **20,000,000** (Two Crore) ordinary shares of **Tk. 10.00** each at par of totaling **Tk. 200,000,000.00** (Twenty Crore).

**(3) Opening and closing date of subscription;**

Opening date of subscription: April 08, 2018  
Closing date of subscription: April 18, 2018

**(4) Availability of full prospectus;**

The Prospectus and abridged version prospectus in hard and soft forms of the Company shall be obtained from the following addresses:

**Issuer:**

| <b>Name &amp; Address</b>  | <b>Telephone &amp; Fax Number, E-mail, Web Address</b>  | <b>Contact Person</b>                                 |
|--|---|---|
| <b>Indo-Bangla Pharmaceuticals Limited (IBPL)</b><br>729, College Road, Barisal Sadar, Barisal-8200. | Tel: +88-04-3161028<br>Fax: +88-04-312174977<br>Email: info@indo-banglapharma.com<br>Web: www.indo-banglapharma.com | <b>Md. Faruque Hossain</b><br>Chief Financial Officer |

**Issue Manager:**

|   |   |   |
|---|---|---|
| <b>AFC Capital Limited</b><br>Saiham Sky View Tower (11 <sup>th</sup> Floor),<br>45 Bijoy Nagar, Dhaka-1000.    | Tel: +88-02-8392371<br>Fax: +88-02-8392372<br>Email: capital.afc@gmail.com<br>Web: www.afcl.asia                  | <b>Mahbub H. Mazumdar FCMA</b><br>Chief Executive                     |
| <b>EBL Investments Limited</b><br>59 Motijheel C/A, 1 <sup>st</sup> Floor, Dhaka-1000.                          | Tel: +88-02-7118975<br>Fax: +88-02-7120251<br>E-mail: info@eblinvestments.com<br>Web: www.eblinvestments.com      | <b>Pankaj Kumar Mutsuddi</b><br>Managing Director<br>(Current Charge) |
| <b>CAPM Advisory Limited</b><br>Tower Hamlet (9th Floor)<br>16, Kemal Ataturk Avenue<br>Banani C/A, Dhaka-1213. | Tel: +88-02-9822391-2<br>Fax: +88-02-9822393<br>E-mail: contact@capmadvisorybd.com<br>Web: www.capmadvisorybd.com | <b>Tania Sharmin</b><br>Managing Director & CEO                       |

**Stock Exchange:**

| <b>Name &amp; Address</b>   | <b>Telephone &amp; Fax Number, E-mail, Web Address</b>   | <b>Contact Person</b>                             |
|---|--|---|
| <b>Dhaka Stock Exchange Limited</b><br>DSE Library, 9/F Motijheel C/A,<br>Dhaka-1000.   | Tel: +88-02-9564601, 9576210-18<br>Fax: +88-02-9564727,<br>+88-02-9569755<br>E-mail: reasearch@dsebd.org<br>Web: www.dsebd.org | <b>Afzalur Rahaman</b><br>Manager                 |
| <b>Chittagong Stock Exchange Limited</b><br>CSE Library, CSE Building, 1080,<br>Sheikh Mujib Road Agrabad,<br>Chittagong- 4100. | Tel: 031-714632-3<br>Fax: 031-714101<br>E-mail: jabed@cse.com.bd<br>Web: www.cse.com.bd  | <b>Mohammed Javed Sarwar</b><br>Assistant Manager |

Prospectus would also be available on the web sites of BSEC (www.sec.gov.bd) at the Public Reference Room of the Bangladesh Securities and Exchange Commission (BSEC) for reading and studying.

**(5) Name of the credit rating Company (if any) along with rating assigned with date of validity;**  
Not applicable for Indo-Bangla Pharmaceuticals Limited.

**(6) Names of the valuer, if any and the auditors;**

**Valuer:** Not applicable for Indo-Bangla Pharmaceuticals Limited.

**Auditor:**

| <b>Name &amp; Address</b>  | <b>Telephone &amp; Fax Number, E-mail, Web Address</b>   | <b>Contact Person</b>            |
|--|--|----------------------------------|
| <b>Mahfel Huq &amp; Co.</b><br>Chartered Accountants<br>BGIC Tower (4 <sup>th</sup> Floor), 34, Topkhana<br>Road Dhaka-1000. | Tel: +88-02-9553143, +88-02-9581786<br>Fax: +88-02-9571005<br>E-mail: mh@mahfelhuq.com<br>Web: www.mahfelhuq.com | <b>Md. Abul Kalam</b><br>Manager |

- (7) A person interested to get a prospectus may obtain from the issuer and the issue manager.
- (8) “If you have any query about this document, you may consult the issuer, issue manager and underwriter”
- (9) “CONSENT OF THE BANGLADESH SECURITIES AND EXCHANGE COMMISSION HAS BEEN OBTAINED TO THE ISSUE/OFFER OF THESE SECURITIES UNDER THE SECURITIES AND EXCHANGE ORDINANCE, 1969, AND THE BANGLADESH SECURITIES AND EXCHANGE COMMISSION (PUBLIC ISSUE) RULES, 2015. IT MUST BE DISTINCTLY UNDERSTOOD THAT IN GIVING THIS CONSENT THE COMMISSION DOES NOT TAKE ANY RESPONSIBILITY FOR THE FINANCIAL SOUNDNESS OF THE ISSUER COMPANY, ANY OF ITS PROJECTS OR THE ISSUE PRICE OF ITS SECURITIES OR FOR THE CORRECTNESS OF ANY OF THE STATEMENTS MADE OR OPINION EXPRESSED WITH REGARD TO THEM. SUCH RESPONSIBILITY LIES WITH THE ISSUER, ITS DIRECTORS, CHIEF EXECUTIVE OFFICER, MANAGING DIRECTOR,/CHIEF FINANCIAL OFFICER, COMPANY SECRETARY, ISSUE MANAGER, ISSUE MANAGER'S CHIEF EXECUTIVE OFFICER, MANAGING DIRECTOR, UNDERWRITERS, AUDITOR(S) AND/OR VALUER, CREDIT RATING COMPANY (IF ANY);

(10)

“পুঁজিবাজারে বিনিয়োগ ঝুঁকিপূর্ণ। জেনে ও বুঝে বিনিয়োগ করুন”

“Investment in capital market involves certain degree of risks. The investors are required to read the prospectus and risk factors carefully, assess their own financial conditions and risk taking ability before making their investment decisions.”

(11) Summary of use of proceeds of the offer;

**Sources of Fund:**

| Issue size<br>(Number of share to be issued) | Issue price | Amount in Taka     |
|--|-------------|--------------------|
| 20,000,000 Shares                            | Tk. 10.00   | 200,000,000        |
| Less: IPO Expenses                           |             | 16,700,000         |
| <b>Net IPO Proceeds</b>                      |             | <b>183,300,000</b> |


**Use of the net proceeds from the IPO:**

Proceeds from Initial Public Offering (IPO) will be used for Construction and other civil works, for procuring machineries and for IPO Expenses.

Details of the estimated project cost for this expansion project and financing has been planned as under:

| Sl. | Particulars                        | Amount in Tk.      |
|-----|------------------------------------|--------------------|
| 1   | Construction and other civil works | 58,580,000         |
| 2   | Machineries                        | 124,720,000        |
|     | <b>Total</b>                       | <b>183,300,000</b> |

**(12) Brief corporate directory of the issuer;**

|                             |   |  |
|-----------------------------|---|--|
| Name of the Company         | : | Indo-Bangla Pharmaceuticals Limited (IBPL)   |
| Company Logo                | : |   |
| Legal Position              | : | Indo-Bangla Pharmaceuticals Limited was incorporated as a private Limited Company under the Companies Act 1994 on 18 June, 2014 vide registration no. C-116665/14. The company has been converted into public limited company on 21 October, 2014. |
| Authorized Capital          | : | Tk. 1,000,000,000 divided into 100,000,000 Ordinary Share of Tk. 10.00 each  |
| Paid up Capital             | : | Tk. 730,000,000 divided into 73,000,000 Ordinary Share of Tk. 10.00 each   |
| Corporate Office            | : | Plot No. # 183 (6 <sup>th</sup> Floor), Block # B, Ahmed Akbar Sobhan Road, Bashundhara R/A, Baridhara, Dhaka-1229.<br>Tel: +88-09678777995<br>Fax: +88-09678777995 (Ext-101)  |
| Registered Office & Factory | : | 729, College Road, Barisal Sadar, Barisal-8200.<br>Tel: +88-04-3161028<br>Fax: +88-04-312174977  |
| Email                       | : | info@indo-banglapharma.com   |
| Web                         | : | www.indo-banglapharma.com  |
| Board of Directors          | : | 12 Directors   |
| Auditors                    | : | Mahfel Huq & Co.<br>Chartered Accountants<br>BGIC Tower (4 <sup>th</sup> Floor), 34, Topkhana Road Dhaka-1000.<br>Tel: +88-02-9553143, +88-02-9581786<br>Fax: +88-02-9571005<br>E-mail: mh@mahfelhuq.com   |
| Manager to the Issue        | : | AFC Capital Limited, EBL Investments Limited & CAPM Advisory Limited.  |
| Banker for IPO              | : | Eastern Bank Limited   |
| Legal Advisors              | : | Md. Atikur Rahman Riaz<br>Advocate   |
| Compliance Officer          | : | Md. Faruque Hossain<br>Chief Financial Officer   |

The Company has no Tax Consultant.

**(13) Location of the project;**

The factory of IBPL is located at 729, College Road, Barisal Sadar, Barisal-8200.

**(14) Principal products or services of the issuer;**

Indo-Bangla Pharmaceuticals Ltd. produces a good number of products of Human products division. All the products of Indo-Bangla Pharmaceuticals Ltd. categorized under Non-Biological Products and Biological Products. List of the products are mentioned below:

**List of Non-Biological Products:**

| SL | Brand Name      | Generic Name  | Dosages Form | Strength  | DAR No.   | Valid up to |
|----|-----------------|---|--------------|---|-----------|-------------|
| 01 | Indostin-R 150  | Ranitidine Hydrochloride USP  | Tablet       | 167.40 mg. (Equivalent to 150.00 mg. Ranitidine)        | 032-93-60 | 22.11.2019  |
| 02 | Indophyllin     | Aminophylline BP  | Tablet       | 100.00 mg.  | 032-20-18 | 22.11.2019  |
| 03 | Mebendox 30ml   | Mebendazole BP  | Suspension   | 2.0 gm / 100ml  | 032-24-55 | 22.11.2018  |
| 04 | Metrol 60ml     | Metronidazole Benzoate BP   | Suspension   | 6.40 gm. (Equivalent to 4.00 gm. Metronidazole) / 100ml | 032-26-56 | 08.12.2020  |
| 05 | Albendox        | Albendazole USP   | Tablet       | 400.00 mg.  | 032-27-55 | 08.12.2020  |
| 06 | Metrol 400mg    | Metronidazole BP  | Tablet       | 400.00 mg.  | 032-25-56 | 25.10.2021  |
| 07 | Paracetamol     | Paracetamol BP  | Tablet       | 500.00 mg.  | 032-18-06 | 25.10.2021  |
| 08 | Indosin         | Chlorpheniramine Maleate BP   | Tablet       | 4.00 mg.  | 032-83-28 | 12.12.2019  |
| 09 | Indosin 100ml   | Chlorpheniramine Maleate BP   | Syrup        | 100.00 mg. / 100ml                                      | 032-84-28 | 12.12.2019  |
| 10 | Naldic          | Nalidixic Acid BP   | Tablet       | 500.00 mg.  | 032-85-60 | 22.11.2019  |
| 11 | I-B Oral Saline | Sodium Chloride BP, Tri Sodium Citrate Dihydrate BP, Potassium Chloride BP & Glucose Anhydrous BP | Oral Saline  | 1.30 gm, 1.45 gm, 0.75 gm & 6.75 gm                     | 032-88-69 | 25.10.2021  |

|    |                      |   |            |   |           |            |
|----|----------------------|---|------------|---|-----------|------------|
| 12 | Inket                | Ketorolac Tromethamine USP                                | Tablet     | 10.00 mg.   | 032-82-65 | 25.10.2021 |
| 13 | Indoflam 400mg       | Ibuprofen BP  | Tablet     | 400.00 mg.  | 032-58-65 | 20.11.2018 |
| 14 | Indoflam 60/100ml    | Ibuprofen BP  | Suspension | 2.00 gm / 100ml   | 032-59-65 | 08.12.2021 |
| 15 | Clear Plus           | Sodium Thiosulphate USP                                   | Tablet     | 15.00 mg.   | 032-77-95 | 20.11.2018 |
| 16 | Clear                | Sodium Thiosulphate USP                                   | Tablet     | 7.50 mg.  | 032-78-95 | 22.11.2019 |
| 17 | Dextrin              | Dexamethasone BP  | Tablet     | 0.50 mg.  | 032-57-50 | 15.10.2021 |
| 18 | Frusidin             | Frusemide BP  | Tablet     | 40.00 mg.   | 032-55-42 | 22.12.2020 |
| 19 | Gyfusin              | Criseofulvin BP   | Tablet     | 500.00 mg.  | 032-56-62 | 22.12.2020 |
| 20 | I-Cin                | Indomethacin BP   | Capsule    | 25.00 mg.   | 032-52-65 | 29.10.2021 |
| 21 | Tensareal            | Diazepam BP   | Tablet     | 5.00 mg.  | 032-63-02 | 19.10.2021 |
| 22 | I-Pedom              | Domperidone Maleate BP                                    | Tablet     | 12.726 mg. (Equivalent to 10.00 mg. Domperidone)                | 032-53-32 | 23.07.2019 |
| 23 | I-Pedom 60/100ml     | Domperidone BP  | Suspension | 100.00 mg. / 100ml  | 032-54-32 | 23.07.2019 |
| 24 | I-Solone             | Prednisolone BP   | Tablet     | 5.00 mg   | 032-79-50 | 19.12.2018 |
| 25 | I-Zam                | Clobazam BP   | Tablet     | 10.00 mg.   | 032-64-09 | 08.11.2020 |
| 26 | Puretab Plus         | Halazone USP  | Tablet     | 15.00 mg.   | 032-80-95 | 12.11.2019 |
| 27 | Puretab              | Halazone USP  | Tablet     | 7.50 mg.  | 032-81-95 | 12.11.2019 |
| 28 | Relise               | Aceclofenac BP  | Tablet     | 10.00 mg.   | 032-60-65 | 15.10.2021 |
| 29 | Sulbumol             | Salbutamol Sulphate BP                                    | Tablet     | 2.40 mg. (Equivalent to 2.00 mg. Salbutamol)                    | 032-67-18 | 20.11.2020 |
| 30 | Sulbumol Plus        | Salbutamol Sulphate BP                                    | Tablet     | 4.80 mg. (Equivalent to 4.00 mg. Salbutamol)                    | 032-68-18 | 20.11.2020 |
| 31 | Sulbumol 60/100ml    | Salbutamol Sulphate BP                                    | Syrup      | 48.00mg. (Equivalent to 2.00mg. Salbutamol) /100ml              | 032-69-18 | 20.11.2020 |
| 32 | Metrol 200mg         | Metronidazole BP  | Tablet     | 200.00 mg.  | 032-09-56 | 19.10.2021 |
| 33 | Paramol 60ml         | Paracetamol BP  | Suspension | 2.40 gm. / 100ml  | 032-22-06 | 19.10.2021 |
| 34 | Mebendox 100mg       | Mebendazole BP  | Tablet     | 100.00 mg   | 032-17-55 | 19.10.2021 |
| 35 | Arromin 60ml & 100ml | Promethazine Hydrochloride BP                             | Elixir     | 100.00 mg. / 100ml  | 032-15-28 | 19.10.2021 |
| 36 | Trialugel            | Aluminium Hydroxide Dried Gel BP & Magnesium Hydroxide BP | Tablet     | 250.00 mg. & 400.00 mg.   | 032-12-29 | 19.10.2021 |
| 37 | Indomol Plus         | Paracetamol BP & Caffeine BP                              | Tablet     | 500.00 mg. & 65.00 mg.  | 032-45-06 | 15.10.2021 |
| 38 | Indofenac - SR       | Diclofenac Sodium BP (Time Release Pellets)               | Capsule    | 250.00 mg. Pellets (Equivalent to 100.00 mg. Diclofenac Sodium) | 032-49-06 | 19.10.2021 |
| 39 | Protobit             | Omeprazole BP (Enteric Coated Pellets)                    | Capsule    | 240.00 mg. Pellets (Equivalent to 20.00 mg. Omeprazole)         | 032-44-29 | 15.10.2021 |
| 40 | Indoprox 250mg       | Naproxen Sodium USP                                       | Tablet     | 275.00 mg. (Equivalent to 250.00 mg. Naproxen)                  | 032-47-65 | 29.10.2021 |
| 41 | Indoprox 500mg       | Naproxen Sodium USP                                       | Tablet     | 550.00 mg. (Equivalent to 500.00 mg. Naproxen)                  | 032-46-65 | 19.10.2021 |
| 42 | Indo-Fila            | Diethyl Carbamazine Citrate BP                            | Tablet     | 100.00 mg.  | 032-43-55 | 08.07.2018 |
| 43 | I-Cet                | Cetirizine Hydrochloride BP                               | Syrup      | 100.00 mg. / 100ml  | 032-41-28 | 19.10.2021 |
| 44 | I-Cet                | Cetirizine Hydrochloride BP                               | Tablet     | 10.00 mg.   | 032-40-28 | 15.10.2021 |
| 45 | Zins                 | Zinc Sulphate Monohydrate USP                             | Syrup      | 549.33mg. (Equivalent to 200.00 mg. Elemental Zinc)             | 032-39-67 | 19.10.2021 |
| 46 | Caltab               | Calcium Lactate BP  | Tablet     | 300.00 mg.  | 032-29-67 | 19.10.2021 |
| 47 | Indocal              | Calcium Carbonate BP                                      | Tablet     | 1250.00mg (Equivalent to 500.00mg. Elemental Calcium)           | 032-38-67 | 19.10.2021 |

### List of Biological Products:

| SL | Brand Name             | Generic Name  | Dosages Form               | Strength   | DAR No.   | Valid up to |
|----|------------------------|---|----------------------------|--|-----------|-------------|
| 01 | Indocef 500mg          | Cephadrine Monohydrate (Compacted) BP   | Capsule                    | 525.00 mg. (Equivalent to 500.00 mg. Cephadrine)                               | 032-89-60 | 23.11.2019  |
| 02 | Indocef DS 100ml       | Cephadrine Monohydrate (Micronised) BP  | Powder for Suspension      | 5.25 gm. (Equivalent to 5.00gm. Cephadrine)/100ml                              | 032-90-60 | 23.11.2019  |
| 03 | Indocef 100ml          | Cephadrine Monohydrate (Micronised) BP  | Powder for Suspension      | 2.625 gm. (Equivalent to 2.50gm. Cephadrine)/100ml                             | 032-91-60 | 23.11.2019  |
| 04 | Indocef 15ml           | Cephadrine Monohydrate (Micronised) BP  | Powder for Paediatric Drop | 1.575 gm. (Equivalent to 1.50gm. Cephadrine) / 15ml                            | 032-91-60 | 23.11.2019  |
| 05 | Cotrimox-DS            | Sulphamethoxazole BP & Trimethoprim BP  | Tablet                     | 800.00 mg. & 160.00 mg.  | 032-28-59 | 25.10.2021  |
| 06 | Insoplex 100ml & 200ml | Thiamine Hydrochloride(B <sub>1</sub> ) BP, Riboflavin -5- Phosphate Sodium(B <sub>2</sub> ) BP, Pyridoxine Hydrochloride(B <sub>6</sub> ) BP & Nicotinamide BP | Syrup                      | (100.00 mg, 54.80 mg, 40.00 mg, & 400.00 mg) / 100ml                           | 032-21-39 | 19.10.2021  |
| 07 | I Need Z               | Dried Ferrous Sulphate, Folic Acid & Zinc Sulphate (Time Release Pellets) BP/USP  | Capsule                    | 285.00 mg.   | 032-86-39 | 25.10.2021  |
| 08 | BCE                    | Vitamin-C BP, Vitamin-E 50% BP & Betacarotene USP   | Tablet                     | 200.00 mg, 50.00 mg, & 06.00 mg.   | 032-87-39 | 08.12.2018  |
| 09 | Indocal-D              | Calcium Carbonate BP & Vitamin-D <sub>3</sub> BP  | Tablet                     | 1250.00mg. (Equivalent to 500.00mg. Calcium) & 200.00i.u. (as cholecalciferol) | 032-99-39 | 19.10.2021  |
| 10 | Indomoxin 15ml         | Amoxycillin Trihydrate (Micronised) BP  | Paediatric Drops           | 1.725 gm.  | 032-65-60 | 25.10.2021  |

|    |                  |  |                       |   |           |            |
|----|------------------|--|-----------------------|---|-----------|------------|
| 11 | Indozith 15/30ml | Azithromycin Dihydrate USP   | Powder for Suspension | 00.84gm (Equivalent to 00.80gm. Azithromycin)       | 032-72-60 | 15.10.2021 |
| 12 | Indozith 250mg   | Azithromycin Dihydrate USP   | Capsule               | 262.500mg (Equivalent to 250.00mg. Azithromycin)    | 032-70-60 | 29.10.2021 |
| 13 | Indozith 500mg   | Azithromycin Dihydrate USP   | Tablet                | 525.00mg (Equivalent to 500.00mg. Azithromycin)     | 032-71-60 | 15.10.2021 |
| 14 | Cipro-I 750mg    | Ciprofloxacin Hydrochloride USP  | Tablet                | 873.30mg (Equivalent to 750.00mg Ciprofloxacin)     | 032-76-60 | 20.09.2018 |
| 15 | I-Cillin 250mg   | Ampicillin Trihydrate (Compacted) BP   | Capsule               | 288.70mg (Equivalent to 250.00mg Ampicillin)        | 032-73-60 | 09.04.2019 |
| 16 | I-Cillin 500mg   | Ampicillin Trihydrate (Compacted) BP   | Capsule               | 577.40mg (Equivalent to 500.00mg Ampicillin)        | 032-74-60 | 09.04.2019 |
| 17 | I-Cillin 100ml   | Ampicillin Trihydrate (Micronised) BP  | Powder for Suspension | 2.88gm (Equivalent to 2.500gm Ampicillin)           | 032-75-60 | 09.04.2019 |
| 18 | I-Fol            | Ferrous Fumarate BP & Foilc Acid BP  | Tablet                | 200.00 mg. & 200.00 mcg.                            | 032-61-26 | 23.12.2018 |
| 19 | I-Fol Plus       | Ferrous Fumarate BP & Foilc Acid BP  | Tablet                | 200.00 mg. & 400.00 mcg.                            | 032-62-27 | 23.12.2018 |
| 20 | Riboflavine      | Riboflavine BP   | Tablet                | 5.00 mg.  | 032-08-39 | 19.10.2021 |
| 21 | Cotrimox 60ml    | Sulphamethoxazole BP & Trimethoprim BP   | Suspension            | (4.00 gm & 0.80 gm)/100ml                           | 032-16-59 | 12.08.2020 |
| 22 | Cotrimox 480mg   | Sulphamethoxazole BP & Trimethoprim BP   | Tablet                | 400 mg. & 80.00 mg.                                 | 032-11-59 | 12.08.2020 |
| 23 | Auriotone        | Ferrous Sulphate BP  | Syrup                 | 4.00 gm   | 032-23-39 | 20.12.2019 |
| 24 | Indox            | Doxycycline Hydrochloride BP   | Capsule               | 115.00mg. (Equivalent to 100.00mg Doxycycline)      | 032-50-60 | 19.10.2021 |
| 25 | Indomoxin 100ml  | Amoxycillin Trihydrate (Micronised) BP   | Powder for Suspension | 2.875gm (Equivalent to 2.500gm Amoxycillin)         | 032-48-60 | 15.10.2021 |
| 26 | Cipro-I 500mg    | Ciprofloxacin Hydrochloride USP  | Tablet                | 582.20 mg. (Equivalent to 500.00 mg. Ciprofloxacin) | 032-32-60 | 19.10.2021 |
| 27 | Indomoxin 250mg  | Amoxycillin Trihydrate (Compacted) BP  | Capsule               | 287.50mg. (Equivalent to 250.00mg Amoxycillin)      | 032-33-60 | 29.10.2021 |
| 28 | Indomoxin 500mg  | Amoxycillin Trihydrate (Compacted) BP  | Capsule               | 575.00mg. (Equivalent to 500.00 mg Amoxycillin)     | 032-34-60 | 19.10.2021 |
| 29 | Indotetra 500mg  | Tetracycline Hydrochloride BP  | Capsule               | 500.00 mg.  | 032-42-60 | 19.10.2021 |
| 30 | Indoflox 100ml   | Flucloxacillin Sodium BP   | Powder for Suspension | 2.72gm. (Equivalent to 2.50gm Flucloxacillin)       | 032-37-60 | 15.10.2021 |
| 31 | Indoflox 250mg   | Flucloxacillin Sodium BP   | Capsule               | 272.00mg. (Equivalent to 250.00mg. Flucloxacillin)  | 032-35-60 | 29.10.2021 |
| 32 | Indoflox 500mg   | Flucloxacillin Sodium BP   | Capsule               | 544.00mg. (Equivalent to 500.00mg. Flucloxacillin)  | 032-36-60 | 29.10.2021 |
| 33 | Indoplex-B       | Thiamine Hydrochloride(B <sub>1</sub> ) BP, Riboflavine (B <sub>2</sub> ) BP, Pyridoxine Hydrochloride(B <sub>6</sub> ) BP & Nicotinamide BP | Tablet                | 5.00 mg, 2.00 mg, 2.00 mg & 20.00 mg                | 032-30-39 | 19.10.2021 |
| 34 | Indomox 250mg    | Amoxycillin Trihydrate (Compacted) BP  | Tablet                | 287.50mg. (Equivalent to 250.00mg. Amoxycillin)     | 032-31-60 | 29.10.2021 |

*\*Non-Biological Products and Biological Products list as per approved by Directorate General of Drug Administration & Licensing Authority (Drugs), Government of the People's Republic of Bangladesh.*

**(15) Names of associates, subsidiary/related and holding of Issuer Company;**

There are no associates, subsidiary and holding company of Indo-Bangla Pharmaceuticals Limited.

**(16) Name, address and short description of each of the directors;**

**Aziza Yeasmin**

Aziza Yeasmin, W/O- Khandakar Mustafizur Rahman, Address: Police Line Sharak, Maitha, Barguna-8700. She is the Chairman of Indo-Bangla Pharmaceuticals Ltd. She completed Bachelor of Arts degree from National University.

**A F M Anowarul Huq**

AFM Anowarul Huq, S/O- Late Azizul Huq, Address: 729, College Road, Barisal Sadar, Barisal-8200. He completed B. Sc, M.Sc. (Chemistry) and LLB degree from National University. Mr. A F M Anowarul Huq is the Managing Director of Indo-Bangla Pharmaceuticals Ltd. and he has 19 years of Professional experience on Pharmaceuticals. He is also member of Barisal Chamber of Commerce.

**Hafiza Yeasmin**

Hafiza Yeasmin, W/O- Md. Moniruzzaman, Address: Kazi Para, Begumgonj, Noakhali. She completed PHD on Rural People Development from University of Copenhagen (Denmark) dated August 06, 2011. After coming back from Denmark, she involved in Indo-Bangla Pharmaceuticals Ltd. as Director.

**Md. Amin-Ur-Rashid**

Md. Amin-Ur-Rashid, S/O- Late Harun-Ur- Rashid, Address: Akon Bari, 453, West Chandkathi, Jhalokathi. He completed his B. Sc (Botani), M.Sc., MBA, L.L.B from National University. In 2001, he started his business carrier and involved with Indo-Bangla Pharmaceuticals Limited. He has 17 years of professional experience of Pharmaceutical manufacturing industry.

**Sayedra Huq**

Mrs. Sayeda Huq was born in 5 October, 1949 in Barisal. Her father is Late Wazed Mia, mother is Late Khandokar Azimunnesa and spouse is Late Azizul Huq. Her residence address: 729, College Road, Barisal Sadar, Barisal-8200. She has 14 years of professional experience of Pharmaceuticals manufacturing industry.

**Mrs. Fatima Parvin**

Mrs. Fatima Parvin was born in 1 November, 1974 in Barguna. Her father is Dr. Ali Akbar Mia, mother is Most. Setara Begum and spouse is Md. Rejaul Kabir Miraz. Her residence address: House-Chaprashi Bari, Road-Gohorpur, Haritana, Barguna. She has 9 years of professional experience of Pharmaceuticals manufacturing industry.

**Mst. Shahanaz Akter**

Mst. Shahanaz Akter, was born in 18 January, 1980 in Barisal. Her father is Md. Abdus Sobhan Khan, mother is Most. Laily Begum and spouse is Md. Azmol Hossain. Her residence address: Vill-Vodrashon, Po-Minar Bari, Bandar, Narayangonj. She has 8 years of professional experience of Pharmaceuticals manufacturing industry.

**Md. Mizanur Rahman**

Md. Mizanur Rahman, was born in 5 October, 1980 in Barisal. His father is Md. Jalal Hawladar, mother is Mrs. Minara Begum. His residence address: Vill: Shibpasha, Post: Raipasha, Thana: Korapur, Dist.: Barisal. He has 8 years of professional experience of Pharmaceuticals manufacturing industry.

**S.M. Harun Or Rashid**

Mr. S.M. Harun Or Rashid was born in April 1, 1953. His father name is Abdul Karim Sikder and mother name is Mst. Rahima Khanom. His address is House No # 15 (Ground Floor), Road No # 14, Block # D, Pallabi, Mirpur-12, Dhaka-1216. Mr. Harun Or Rashid obtained B.Com. from Dhaka University & has 21 years of Business experience. He also involved with pharmaceuticals industry last 13 years.

**Md. Monirujjaman**

Mr. Md. Monirujjaman was born in April 22, 1979 in Barguna. His father name is Abdur Rab Khan and mother is Nurjahan Begum. His address is South Patharghata, Patharghata-8720, Barguna. He finished Master of law from Dhaka International University. After finishing his educational career, he involved in business. He has 13 years of business experience. He is an Independent Director of Indo-Bangla Pharmaceuticals Ltd.

**Md. Firoz Khan**

Mr. Firoz Khan, has completed B.Sc (Math) and MSc. His address: P.O. Anail Bunia, Thana-Kathalia, Dist-Jhalokati. He is an Independent Director of Indo-Bangla Pharmaceuticals Ltd. Mr. Firoz Khan is the reputed businessman being the Director of Sabila Sea Foods Ltd. He is also the proprietor of Khan Trading Company.

**(17) Comparative financial statements and NAV, EPS, and financial ratios for the last five years or from commercial operation, which is shorter;**

**Auditors' report Under Section-135 (1) and Para-24(1) of Part-II of Schedule-III of the Companies Act 1994**

We have examined the Financial Statements of Indo-Bangla Pharmaceuticals Limited for the year ended June 30, 2015 and 2016 were audited by us. In pursuance of Section-135 (1) and Para-24 (1) of Part-II of Schedule-III of the Companies Act 1994, our report is as under:

**A) Statements of Assets and Liabilities of the company is as under:**

| Particulars                            | Amount in Taka     |                    |
|--|--------------------|--------------------|
|  | 30-Jun-16          | 30-Jun-15          |
|  |                    | Restated           |
| <b>APPLICATION OF FUND</b>             |                    |                    |
| <b>NON-CURRENT ASSETS</b>              |                    |                    |
| Property, Plant and Equipment          | 211,400,486        | 147,873,513        |
| Work in Progress                       | 119,069,371        | 10,401,337         |
| <b>Total Non-Current Assets</b>        | <b>330,469,857</b> | <b>158,274,850</b> |
| <b>CURRENT ASSETS</b>                  |                    |                    |
| Inventories                            | 156,521,360        | 142,164,099        |
| Trade & Other Receivables              | 112,266,319        | 41,438,482         |
| Advance, Deposits and Prepayments      | 105,325,972        | 35,253,978         |
| Cash and Cash equivalents              | 240,795,305        | 5,888,123          |
| <b>Total Current Assets</b>            | <b>614,908,956</b> | <b>224,744,682</b> |
| <b>TOTAL ASSETS</b>                    | <b>945,378,813</b> | <b>383,019,532</b> |
| <b>OWNER'S EQUITY</b>                  |                    |                    |
| Share Capital                          | 730,000,000        | 99,000,000         |
| Retained Earnings                      | 119,233,972        | 60,209,267         |
| <b>Total Equity</b>                    | <b>849,233,972</b> | <b>159,209,267</b> |
| <b>NON-CURRENT LIABILITIES</b>         |                    |                    |
| Deferred Tax Liability                 | 9,283,317          | 4,022,794          |
| Provision for WPPF                     | 4,540,362          | -                  |
|  | <b>13,823,679</b>  | <b>4,022,794</b>   |
| <b>CURRENT LIABILITIES</b>             |                    |                    |
| Trade and other Payables               | 15,911,787         | 11,847,860         |
| Vendors payable Account                | -                  | 171,837,213        |
| Provision for Taxes                    | 54,919,591         | 28,397,581         |
| Liabilities for Expenses               | 11,489,784         | 7,704,817          |
| <b>TOTAL CURRENT LIABILITIES</b>       | <b>82,321,162</b>  | <b>219,787,471</b> |
| <b>TOTAL LIABILITIES</b>               | <b>96,144,841</b>  | <b>223,810,265</b> |
| <b>TOTAL EQUITY AND LIABILITIES</b>    | <b>945,378,813</b> | <b>383,019,532</b> |
| <b>Net Asset Value (NAV) per Share</b> | 11.63              | 16.08              |



**B) The statements of operating results of the company is as follow:**

| Particulars  | Amount in Taka     |                    |
|--|--------------------|--------------------|
|  | 30-Jun-16          | 30-Jun-15          |
|  |                    | Restated           |
| Net Sales Revenue  | 444,777,724        | 435,024,108        |
| Cost of Goods Sold   | 262,528,992        | 257,883,659        |
| <b>Gross Profit</b>  | <b>182,248,732</b> | <b>177,140,449</b> |
| <b>Operating Expenses:</b>                                   | <b>87,751,623</b>  | <b>84,720,465</b>  |
| Administrative Expenses                                      | 23,381,246         | 22,007,014         |
| Selling & Distributing Expenses                              | 64,370,377         | 62,713,451         |
| <b>Profit from Operations</b>                                | <b>94,497,109</b>  | <b>92,419,984</b>  |
| Non-Operating Income   | 850,491            | 209,658            |
| <b>Profit before Contribution to WPPF &amp; Welfare Fund</b> | <b>95,347,600</b>  | <b>92,629,642</b>  |
| Contribution to WPPF & Welfare Fund                          | 4,540,362          | -                  |
| <b>Profit before Tax</b>                                     | <b>90,807,238</b>  | <b>92,629,642</b>  |
| <b>Provision for Taxation:</b>                               | <b>31,782,533</b>  | <b>32,420,375</b>  |
| Income Tax Current year                                      | 26,522,010         | 28,397,581         |
| Deferred Tax Current year                                    | 5,260,523          | 4,022,794          |
| <b>Profit after tax</b>                                      | <b>59,024,705</b>  | <b>60,209,267</b>  |
| <b>Earnings per Share (Basic)</b>                            | 2.62               | 6.40               |

**C. Dividend declared:**

| Particulars                  | 30-Jun-16 | 30-Jun-15 |
|------------------------------|-----------|-----------|
| Cash Dividend                | Nil       | Nil       |
| Stock Dividend (Bonus Share) | Nil       | Nil       |

- D. Indo-Bangla Pharmaceuticals Limited (IBPL) was incorporated in Bangladesh as a Private Limited Company with the issuance of Certificate of incorporation bearing no. C-116665/14 dated on June 18, 2014 by the Registrar of Joint Stock Companies & Firms. The Company Converted into public Limited Company on October 21, 2014.
- E. The Company started its commercial operation in June 18, 2014.
- F. No proceeds or part of the proceeds of the issue of shares would be applied directly by the company in the purchase of any business.
- G. The Company did not prepare any statement of accounts for the year subsequent to June 30, 2016.
- H. Figures related to previous years have been re-arranged whenever considered necessary.

**Place:** Dhaka  
**Date:** September 24, 2016

Sd/-  
**Mahfel Huq & Co.**  
Chartered Accountants

### Auditor's certificate regarding calculation of EPS and Ratios

This is to certify that Indo-Bangla Pharmaceuticals Limited has maintained the following ratios as computed on the basis of the audited financial statements for the year ended June 30, 2016 and 2015.

| Particulars | 30-Jun-2016 |  | 30-Jun-2015 |
|-------------|-------------|--|-------------|
|             | Ratio       |  |             |

#### I. Liquidity Ratios:

|                   |      |  |      |
|-------------------|------|--|------|
| (i) Current Ratio | 7.47 |  | 1.02 |
| (ii) Quick Ratio  | 4.29 |  | 0.22 |

#### II. Operating Efficiency Ratios:

|  |      |  |       |
|--|------|--|-------|
| (i) Accounts Receivable Turnover Ratio | 5.79 |  | 10.50 |
| (ii) Inventory Turnover Ratio          | 1.76 |  | 1.81  |
| (iii) Asset Turnover Ratio             | 0.67 |  | 1.14  |

#### III. Profitability Ratios:

|                                     |        |  |        |
|-------------------------------------|--------|--|--------|
| (i) Gross Margin Ratio              | 40.98% |  | 40.72% |
| (ii) Operating Profit Ratio         | 21.25% |  | 21.24% |
| (iii) Net Profit Ratio              | 13.27% |  | 13.84% |
| (iv) Return on Assets Ratio         | 8.89%  |  | 15.72% |
| (v) Return on Equity Ratio          | 11.71% |  | 37.82% |
| (vi) Basic Earnings Per Share (EPS) | 2.62   |  | 6.40   |
| (vii) EBITDA Margin                 | 22.49% |  | 22.09% |

#### IV. Solvency Ratios:

|                                   |   |  |   |
|-----------------------------------|---|--|---|
| (i) Debt to Total Assets Ratio    | - |  | - |
| (ii) Debt to Equity Ratio         | - |  | - |
| (iii) Times Interest Earned Ratio | - |  | - |
| (iv) Debt Service Coverage Ratio  | - |  | - |

#### V. Cash Flow Ratios:

|  |      |  |      |
|--|------|--|------|
| (i) Net Operating Cash Flow per Share (NOCFPS) | 0.19 |  | 7.56 |
| (ii) NOCFPS to EPS Ratio                       | 0.07 |  | 1.18 |

Place: Dhaka

Date: October 01, 2017

Sd/-  
**Mahfel Huq & Co.**  
Chartered Accountants

## **(18) Public issue application process:**

### **Step-1 (Applicant)**

1. An applicant for public issue of securities shall submit application/buy instruction to the Stockbroker/Merchant Banker where the applicant maintains customer account, within the cut-off date (i.e. the subscription closing date), which shall be the **25th (twenty fifth) working day** from the date of publication of abridged version of prospectus.
2. The application/buy instruction may be submitted in prescribed paper or electronic form, which shall contain the Customer ID, Name, BO Account Number, Number of Securities applied for, Total Amount and Category of the Applicant. At the same time:
  - a. Other than non-resident Bangladeshi (NRB) and Foreign applicants shall make the application money and service charge available in respective customer account maintained with the Stockbroker/Merchant Banker. No margin facility, advance or deferred payment is permissible for this purpose. In case the application is made through a margin account, the application money shall be deposited separately and the Stockbroker/Merchant Banker shall keep the amount segregated from the margin account, which shall be refundable to the applicant, if become unsuccessful.
  - b. Non-resident Bangladeshi (NRB) and Foreign applicants shall submit bank drafts (FDD), issued in favor of the Issuer for an amount equivalent to the application money, with their application to the concerned Stockbroker/Merchant Banker. A Non-resident Bangladeshi (NRB) and Foreign applicant may also submit a single draft against 02(two) applications made by him/her, i.e. one in his/her own name and the other jointly with another person. The draft (FDD) shall be issued by the Bank where the applicant maintains Foreign Currency account debiting the same account and provide the customer with a certificate mentioning the FC account number which has been debited to issue the FDD. The applicant shall also submit the certificate with their application. No banker shall issue more than two drafts from any Foreign Currency account for any public issue. At the same time, the applicant shall make the service charge available in respective customer account maintained with the Stockbroker/Merchant Banker.
  - c. Eligible investors shall submit application through the electronic subscription system of the exchange(s) and deposit the full amount intended to subscribe by the method as determined by the exchange(s).

### **Step-2 (Intermediary)**

3. The Stockbroker/Merchant Banker shall maintain a separate bank account only for this purpose namely "Public Issue Application Account". The Stockbroker/Merchant Banker shall:
  - a. post the amount separately in the customer account (other than NRB and Foreign applicants), and upon availability of fund, block the amount equivalent to the application money;
  - b. accumulate all the application/buy instructions received up to the cut-off date, deposit the amount in the "Public Issue Application Account" maintained with its bank within the first banking hour of next working day of the cut-off date;
  - c. instruct the banker to block the account for an amount equivalent to the aggregate application money and to issue a certificate in this regard.
4. Banker of the Stockbroker/Merchant Banker shall block the account as requested for, issue a certificate confirming the same and handover it to the respective Stockbroker/Merchant Banker.
5. For Non-resident Bangladeshi (NRB) and Foreign applicants, the Stockbroker/Merchant Banker shall prepare a list containing the draft information against the respective applicant's particulars.

6. The Stockbroker/Merchant Banker shall prepare category-wise lists of the applicants containing Customer ID, Name, BO Account Number and Number of Securities applied for, and within 03 (three) working days from the cut-off date, send to the respective Exchange, the lists of applicants in electronic (text format with tilde '~' separator) format, the certificate(s) issued by its banker, the drafts and certificates received from Non-resident Bangladeshi (NRB) and Foreign applicants and a copy of the list containing the draft information.
7. On the next working day, the Exchanges shall provide the Issuer with the information received from the Stockbroker/Merchant Bankers, the drafts and certificates submitted by Non-resident Bangladeshi (NRB) and Foreign applicants and the list containing the draft information. Exchanges shall verify and preserve the bankers' certificates in their custody.
8. The application/buy instructions shall be preserved by the Stockbroker/Merchant Bankers up to 6 months from listing of the securities with exchange.

### **Step-3 (Issuer)**

9. The Issuer shall prepare consolidated list of the applications and send the applicants' BOIDs in electronic (text) format in a CDROM to CDBL for verification. The Issuer shall post the consolidated list of applicants on its website and websites of the Exchanges. CDBL shall verify the BOIDs as to whether the BO accounts of the applicants are active or not.
10. On the next working day, CDBL shall provide the Issuer with an updated database of the applicants containing BO Account Number, Name, Addresses, Parents Name, Joint Account and Bank Account information along with the verification report.
11. After receiving verification report and information from CDBL, the Issuer shall scrutinize the applications, prepare category wise consolidated lists of valid and invalid applications and submit report of final status of subscription to the Commission and the Exchanges within 10 (ten) working days from the date of receiving information from the Exchanges.
12. The Issuer and the issue manager shall conduct category wise lottery with the valid applications within 03 (three) working days from the date of reporting to the Commission and the Exchanges, if do not receive any observation from the Commission or the Exchanges.
13. The Issuer and issue manager shall arrange posting the lottery result on their websites within 06 (six) hours and on the websites of the Commission and Exchanges within 12 (twelve) hours of lottery.
14. Within 02 (two) working days of conducting lottery, the Issuer shall:
  - a. send category wise lists of the successful and unsuccessful applicants in electronic (text format with tilde '~' separator) format to the respective Exchange.
  - b. send category wise lists of unsuccessful applicants who are subject to penal provisions as per conditions of the Consent Letter issued by the Commission in electronic (text format with tilde '~' separator) format to the Commission and Exchanges mentioning the penalty amount against each applicant.
  - c. issue allotment letters in the names of successful applicants in electronic format with digital signatures and send those to respective Exchange in electronic form.
  - d. send consolidated allotment data (BOID and number of securities) in electronic text format in a CDROM to CDBL to credit the allotted shares to the respective BO accounts.

#### **Step-4 (Intermediary)**

15. On the next working day, Exchanges shall distribute the information and allotment letters to the Stockbroker/Merchant Bankers concerned in electronic format and instruct them to:
  - a. remit the amount of successful (other than NRB and Foreign) applicants to the Issuer's respective Escrow Account opened for subscription purpose, and unblock the amount of unsuccessful applicants;
  - b. send the penalty amount of other than NRB and Foreign applicants who are subject to penal provisions to the Issuer's respective Escrow Accounts along with a list and unblock the balance application money;
16. On the next working day of receiving the documents from the Exchanges, the Stockbrokers/Merchant Banker shall request its banker to:
  - a. release the amount blocked for unsuccessful (other than NRB and foreign) applicants;
  - b. remit the aggregate amount of successful applicants and the penalty amount of unsuccessful applicants (other than NRB and foreign) who are subject to penal provisions to the respective 'Escrow' accounts of the Issuer opened for subscription purpose.
17. On the next working day of receiving request from the Stockbrokers/Merchant Bankers, their bankers shall unblock the amount blocked in the account(s) and remit the amount as requested for to the Issuer's 'Escrow' account.
18. Simultaneously, the stockbrokers/Merchant Bankers shall release the application money blocked in the customer accounts; inform the successful applicants about allotment of securities and the unsuccessful applicants about releasing their blocked amounts and send documents to the Exchange evidencing details of the remittances made to the respective 'Escrow' accounts of the Issuer. The unblocked amounts of unsuccessful applicants shall be placed as per their instructions. The Stockbroker/Merchant Banker shall be entitled to recover the withdrawal charges, if any, from the applicant who wants to withdraw the application money, up to an amount of Tk. 5.00 (five) per withdrawal.
19. All drafts submitted by NRB or Foreign applicants shall be deposited in the Issuer's respective 'Escrow' accounts and refund shall be made by the Issuer by refund warrants through concerned stockbroker or merchant banker or transfer to the applicant's bank account (FC account which has been debited to apply by NRB or foreign applicants) through banking channel within 10 (ten) working days from the date of lottery.

#### **Miscellaneous:**

20. The Issuer, Issue Manager, Stockbrokers and Merchant Bankers shall ensure compliance of the above.
21. The bank drafts (FDD) shall be issued considering TT Clean exchange rate of Sonali Bank Ltd. on the date of publication of abridged version of prospectus.
22. Amount deposited and blocked in the "Public Issue Application Account" shall not be withdrawn or transferred during the blocking period. Amount deposited by the applicants shall not be used by the Stockbrokers/Merchant Bankers for any purpose other than public issue application.
23. The Issuer shall pay the costs related to data transmission, if claimed by the Exchange concerned up to an amount of Tk.2,00,000.00 (taka two lac) for a public issue.

24. The Stockbroker/Merchant Bankers shall be entitled to a service charge of Tk.5.00 (taka five) only per application irrespective of the amount or category. The service charge shall be paid by the applicant at the time of submitting application.
25. The Stockbroker/Merchant Banker shall provide the Issuer with a statement of the remittance and drafts sent.
26. The Issuer shall accumulate the penalty amount recovered and send it to the Commission through a bank draft/payment order issued in favor of the Bangladesh Securities and Exchange Commission.
27. The concerned Exchange are authorized to settle any complaints and take necessary actions against any Stockbroker/Merchant Banker in case of violation of any provision of the public issue application process with intimation to the Commission.

**All eligible Stock Brokers and Merchant Bankers shall receive the IPO subscription.**

The IPO subscription money collected from successful applicants (other than NRB applicants) by the Stockbrokers/Merchant Bankers will be remitted to the Company's **High Performance Account Corporate No. 1011360459420** with Eastern Bank Limited, Principal Branch, Dhaka, Bangladesh for this purpose.

The IPO subscription money collected from successful NRB applicants in US Dollar or UK Pound Sterling or EURO shall be deposited to three FC accounts opened by the Company for IPO purpose are as follows:

| SL | Name of the A/C | Account No.   | Type of A/C | Currency | Bank & Branch                                    |
|----|-----------------|---------------|-------------|----------|--|
| 1  | Indo-Bangla     | 1013050459441 | FC A/C      | USD      | Eastern Bank Limited,<br>Principal Branch, Dhaka |
| 2  | Pharmaceuticals | 1013060459430 |             | GBP      |  |
| 3  | Limited         | 1013070459408 |             | EUR      |  |